Identification of novel biomarker of heart failure by collecting blood samples from coronary sinus, subclavian vein, and radial artery

Identification of novel biomarker of heart failure by collecting blood samples from coronary sinus, subclavian vein, and radial artery - Identification of novel biomarker of heart failure by collecting blood samples from coronary sinus, subclavian vein, and radial artery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004129

Enrollment

Registered

2010-09-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

We will collect 10mL of blood from radial artery, coronary sinus, and subclavian vein, in patients with heart failure receiving cardiac resynchronization therapy (CRT)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with heart failure receiving cardiac resynchronization therapy (CRT) at Kyoto University Hospital.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
We will measure the blood concentration of the potential biomarkers of heart failure in radial artery, coronary sinus, and subclavian vein. The difference in blood concentration of coronary sinus and radial artery will also be analyzed. The concentrations of potential biomarker molecules will be compared with survival, severity of heart failure, electrocardiography, chest X-ray, blood chemical analyses, known biomarkers of heart failure, echocardiography, cardiac function assessed by radioisotope or MR imaging.	—

Measure

Time frame

We will measure the blood concentration of the potential biomarkers of heart failure in radial artery, coronary sinus, and subclavian vein. The difference in blood concentration of coronary sinus and radial artery will also be analyzed. The concentrations of potential biomarker molecules will be compared with survival, severity of heart failure, electrocardiography, chest X-ray, blood chemical analyses, known biomarkers of heart failure, echocardiography, cardiac function assessed by radioisotope or MR imaging.

—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026